{"id":"liposomal-doxorubicin","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"Reported 97 times"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"Reported 88 times"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"Reported 80 times"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"Reported 80 times"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"Reported 78 times"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"Reported 63 times"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"Reported 57 times"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"Reported 52 times"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 50 times"},{"date":"","signal":"PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME","source":"FDA FAERS","actionTaken":"Reported 50 times"}],"drugInteractions":[{"name":"streptozocin","source":"DrugCentral","severity":"Significant","description":"DOXORUBICIN/STREPTOZOCIN [VA Drug Interaction]"}],"commonSideEffects":[],"contraindications":["Anemia","Anemia due to enzyme deficiency","Asymptomatic left ventricular systolic dysfunction","Atrioventricular block","Bacterial infectious disease","Bone marrow depression","Breastfeeding (mother)","Bundle branch block","Cardiomyopathy","Conduction disorder of the heart","Deficiency of glucose-6-phosphate dehydrogenase","Disease of liver","Heart disease","Heart failure","Hepatic failure","Hyperbilirubinemia","Hyperuricemia","Leukopenia","Mycosis","Myocardial infarction in recovery phase"],"specialPopulations":{"Pregnancy":"Pegylated liposomal doxorubicin is embryotoxic and abortifacient in animal studies and may be teratogenic. Women of childbearing potential should avoid pregnancy while they or their male partners are receiving treatment and for six months following discontinuation. Breastfeeding is not recommended due to the potential secretion into breast milk.","Geriatric use":"Does not affect the pharmacokinetics of this drug.","Paediatric use":"Special pediatric considerations are noted when applicable, otherwise adult provisions apply. No specific information found for children.","Renal impairment":"No adjustment required.","Hepatic impairment":"Adjustment required. Refer to protocol by which patient is being treated. If no guidelines are available, see suggested dose modifications below: For breast or ovarian patients: Total Bilirubin (micromol/L) Dose <21 100%, 21-51 75%, >51 50%. If first dose is tolerated without further increases in bilirubin and/or liver enzymes, subsequent doses may be increased by one dosage level as clinically indicated. For Kaposi’s Sarcoma patients: Bilirubin (micromol/L) Dose <21 100%, 21-51 50%, >51 25%."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:34:37.632145","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=liposomal-doxorubicin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:43.634028+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:49.963055+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:43.659747+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=liposomal-doxorubicin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:50.772596+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:51.369818+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL359744/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:51.282453+00:00"}},"allNames":"liposomal doxorubicin","offLabel":[],"synonyms":["doxorubicin","hydroxydaunomycin","hydroxydaunorubicin","rubidox","doxorubicin hydrochloride","liposomal doxorubicin","hydroxydaunorubicin hydrochloride","adriamycin","doxorubicin HCl","hydroxydaunorubicin HCl","adriacin"],"timeline":[{"date":"1989-01-01","type":"positive","milestone":"Discovery and Initial Development of Liposomal Doxorubicin","regulator":"none"},{"date":"1991-06-01","type":"positive","milestone":"IND Submission for Liposomal Doxorubicin","regulator":"FDA"},{"date":"1992-03-01","type":"positive","milestone":"Phase 1 Clinical Trials Begin","regulator":"none"},{"date":"1993-09-01","type":"positive","milestone":"Phase 2 Clinical Trials Begin","regulator":"none"},{"date":"1995-04-01","type":"positive","milestone":"Phase 3 Clinical Trials Begin","regulator":"none"},{"date":"1995-11-15","type":"positive","milestone":"FDA Approval for Liposomal Doxorubicin","regulator":"FDA"},{"date":"1996-07-01","type":"positive","milestone":"EMA Approval for Liposomal Doxorubicin","regulator":"EMA"},{"date":"2000-01-01","type":"positive","milestone":"Label Expansion for Additional Indications","regulator":"FDA"},{"date":"2005-01-01","type":"neutral","milestone":"Patent Expiry for Liposomal Doxorubicin","regulator":"none"}],"_dailymed":{"setId":"b24afa8c-636b-4ace-99d5-51f445ad3123","title":"DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [BAXTER HEALTHCARE CORPORATION]","labeler":""},"aiSummary":"Liposomal Doxorubicin, developed by Pfizer Inc., is a marketed drug used to treat various cancers. It is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the synthesis of macromolecules. Liposomal Doxorubicin is indicated for acute lymphoid leukemia, acute myeloid leukemia, advanced ovarian cancer, Burkitt's lymphoma, and breast carcinoma. Its clinical differentiation lies in its ability to reduce cardiotoxicity compared to conventional doxorubicin. The commercial significance of Liposomal Doxorubicin is its established market presence and revenue generation. However, pipeline developments for similar drugs may impact its market share.","brandName":"Liposomal Doxorubicin","ecosystem":[],"isGeneric":true,"mechanism":{"target":"72 kDa type IV collagenase","novelty":"Best-in-class","targets":[{"gene":"MMP2","source":"DrugCentral","target":"72 kDa type IV collagenase","protein":"72 kDa type IV collagenase","activityType":"IC50"},{"gene":"ABCG2","source":"DrugCentral","target":"ATP-binding cassette sub-family G member 2","protein":"ATP-binding cassette sub-family G member 2","activityType":""},{"gene":"AURKA","source":"DrugCentral","target":"Aurora kinase A","protein":"Aurora kinase A","activityType":"IC50"},{"gene":"CISD1","source":"DrugCentral","target":"CDGSH iron-sulfur domain-containing protein 1","protein":"CDGSH iron-sulfur domain-containing protein 1","activityType":"Ki"},{"gene":"ABCC2","source":"DrugCentral","target":"Canalicular multispecific organic anion transporter 1","protein":"Canalicular multispecific organic anion transporter 1","activityType":""},{"gene":"CASP1","source":"DrugCentral","target":"Caspase-1","protein":"Caspase-1","activityType":"IC50"},{"gene":"TOP1","source":"DrugCentral","target":"DNA topoisomerase 1","protein":"DNA topoisomerase 1","activityType":"IC50"},{"gene":"TOP2A","source":"DrugCentral","target":"DNA topoisomerase 2-alpha","protein":"DNA topoisomerase 2-alpha","activityType":"IC50"},{"gene":"TOP2B","source":"DrugCentral","target":"DNA topoisomerase 2-beta","protein":"DNA topoisomerase 2-beta","activityType":"IC50"},{"gene":"ABCB1","source":"DrugCentral","target":"Multidrug resistance protein 1","protein":"Multidrug resistance protein 1","activityType":"IC50"}],"modality":"Small molecule","drugClass":"doxorubicin","explanation":"","oneSentence":"","technicalDetail":"Liposomal Doxorubicin exerts its effects by binding to DNA and inhibiting the enzyme topoisomerase II, which is essential for DNA replication and transcription. This results in DNA strand breaks and ultimately leads to cell death. The liposomal formulation of doxorubicin allows for a more targeted delivery of the drug to cancer cells, reducing the risk of cardiotoxicity."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"launchDate":"1974","annualCostUS":"$30,000-40,000/yr (source: GoodRx)","_launchSource":"DrugCentral (FDA 1974-08-07, )","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/960","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=liposomal-doxorubicin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=liposomal-doxorubicin","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":6,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":7,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":8,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_emaChecked":true,"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:53.192817+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Doxil","company":"Janssen Biotech","advantage":"Same active ingredient (doxorubicin) but different formulation; similar uses and side effect profile."},{"name":"Panretin (alitretinoin)","company":"LEO Pharma","advantage":"Topical treatment for Kaposi's sarcoma; different mechanism of action and route of administration."},{"name":"Interferon alfa-2b","company":"Merck & Co.","advantage":"Used for Kaposi's sarcoma; different mechanism of action and route of administration."},{"name":"Pomalyst (pomalidomide)","company":"Celgene Corporation","advantage":"Used for multiple myeloma; different mechanism of action and route of administration."},{"name":"Vinblastine","company":"Various manufacturers","advantage":"Used for Kaposi's sarcoma; different mechanism of action and route of administration."},{"name":"Paclitaxel","company":"Various manufacturers","advantage":"Used for ovarian cancer and other cancers; different mechanism of action and route of administration."}],"genericName":"liposomal-doxorubicin","indications":{"approved":[{"name":"Acute lymphoid leukemia","source":"DrugCentral","snomedId":91857003,"regulator":"FDA"},{"name":"Acute myeloid leukemia, disease","source":"DrugCentral","snomedId":91861009,"regulator":"FDA"},{"name":"Advanced ovarian cancer","source":"DrugCentral","snomedId":363443007,"regulator":"FDA"},{"name":"Burkitt's lymphoma","source":"DrugCentral","snomedId":118617000,"regulator":"FDA"},{"name":"Carcinoma of breast","source":"DrugCentral","snomedId":254838004,"regulator":"FDA"},{"name":"Carcinoma of female breast","source":"DrugCentral","snomedId":447782002,"regulator":"FDA"},{"name":"Diffuse non-Hodgkin's lymphoma, large cell","source":"DrugCentral","snomedId":109969005,"regulator":"FDA"},{"name":"Follicular non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":308121000,"regulator":"FDA"},{"name":"Hodgkin's disease","source":"DrugCentral","snomedId":118599009,"regulator":"FDA"},{"name":"Invasive Bladder Malignancy","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Kaposi's sarcoma","source":"DrugCentral","snomedId":109385007,"regulator":"FDA"},{"name":"Kaposi's sarcoma associated with AIDS","source":"DrugCentral","snomedId":420524008,"regulator":"FDA"},{"name":"Malignant tumor of lung","source":"DrugCentral","snomedId":363358000,"regulator":"FDA"},{"name":"Malignant tumor of ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA"},{"name":"Malignant tumor of thyroid gland","source":"DrugCentral","snomedId":363478007,"regulator":"FDA"},{"name":"Metastatic Breast Carcinoma","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Metastatic Gastric Cancer","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Multiple myeloma","source":"DrugCentral","snomedId":109989006,"regulator":"FDA"},{"name":"Nephroblastoma","source":"DrugCentral","snomedId":302849000,"regulator":"FDA"},{"name":"Neuroblastoma","source":"DrugCentral","snomedId":432328008,"regulator":"FDA"},{"name":"Non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":118601006,"regulator":"FDA"},{"name":"Osteosarcoma of bone","source":"DrugCentral","snomedId":307576001,"regulator":"FDA"},{"name":"Small cell carcinoma of lung","source":"DrugCentral","snomedId":254632001,"regulator":"FDA"},{"name":"Soft or Connective Tissue Sarcoma","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Adenocarcinoma of pancreas","source":"DrugCentral"},{"name":"Carcinoid syndrome","source":"DrugCentral"},{"name":"Chronic lymphoid leukemia, disease","source":"DrugCentral"},{"name":"Endometrial carcinoma","source":"DrugCentral"},{"name":"Ewing's sarcoma","source":"DrugCentral"},{"name":"Malignant neoplasm of liver","source":"DrugCentral"},{"name":"Malignant tumor of head and/or neck","source":"DrugCentral"},{"name":"Pancreatic Neuroendocrine Tumor","source":"DrugCentral"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral"}],"pipeline":[]},"_drugCentral":{"patents":[],"targets":[{"gene":"MMP2","target":"72 kDa type IV collagenase","protein":"72 kDa type IV collagenase","activityType":"IC50","activityUnit":"","activityValue":5.96},{"gene":"ABCG2","target":"ATP-binding cassette sub-family G member 2","protein":"ATP-binding cassette sub-family G member 2","activityType":"","activityUnit":"","activityValue":null},{"gene":"AURKA","target":"Aurora kinase A","protein":"Aurora kinase A","activityType":"IC50","activityUnit":"","activityValue":7.4},{"gene":"CISD1","target":"CDGSH iron-sulfur domain-containing protein 1","protein":"CDGSH iron-sulfur domain-containing protein 1","activityType":"Ki","activityUnit":"","activityValue":5.46},{"gene":"ABCC2","target":"Canalicular multispecific organic anion transporter 1","protein":"Canalicular multispecific organic anion transporter 1","activityType":"","activityUnit":"","activityValue":null},{"gene":"CASP1","target":"Caspase-1","protein":"Caspase-1","activityType":"IC50","activityUnit":"","activityValue":4.914},{"gene":"TOP1","target":"DNA topoisomerase 1","protein":"DNA topoisomerase 1","activityType":"IC50","activityUnit":"","activityValue":4.7},{"gene":"TOP2A","target":"DNA topoisomerase 2-alpha","protein":"DNA topoisomerase 2-alpha","activityType":"IC50","activityUnit":"","activityValue":6},{"gene":"TOP2B","target":"DNA topoisomerase 2-beta","protein":"DNA topoisomerase 2-beta","activityType":"IC50","activityUnit":"","activityValue":5.46},{"gene":"ABCB1","target":"Multidrug resistance protein 1","protein":"Multidrug resistance protein 1","activityType":"IC50","activityUnit":"","activityValue":4.01},{"gene":"ABCC1","target":"Multidrug resistance-associated protein 1","protein":"Multidrug resistance-associated protein 1","activityType":"","activityUnit":"","activityValue":null},{"gene":"ABCC6","target":"Multidrug resistance-associated protein 6","protein":"Multidrug resistance-associated protein 6","activityType":"","activityUnit":"","activityValue":null},{"gene":"CHRM1","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1","activityType":"Ki","activityUnit":"","activityValue":5.433},{"gene":"ERBB2","target":"Receptor tyrosine-protein kinase erbB-2","protein":"Receptor tyrosine-protein kinase erbB-2","activityType":"IC50","activityUnit":"","activityValue":5.605},{"gene":"TERT","target":"Telomerase reverse transcriptase","protein":"Telomerase reverse transcriptase","activityType":"IC50","activityUnit":"","activityValue":4.14},{"gene":"FYN","target":"Tyrosine-protein kinase Fyn","protein":"Tyrosine-protein kinase Fyn","activityType":"IC50","activityUnit":"","activityValue":5.288},{"gene":"LCK","target":"Tyrosine-protein kinase Lck","protein":"Tyrosine-protein kinase Lck","activityType":"IC50","activityUnit":"","activityValue":4.496}],"atcCodes":["L01DB01"],"synonyms":["doxorubicin","hydroxydaunomycin","hydroxydaunorubicin","rubidox","doxorubicin hydrochloride","liposomal doxorubicin","hydroxydaunorubicin hydrochloride","adriamycin","doxorubicin HCl","hydroxydaunorubicin HCl","adriacin"],"approvals":[{"date":"1974-08-07","orphan":false,"company":"","regulator":"FDA"},{"date":"1975-03-01","orphan":false,"company":"SANDOZ PHARMA K.K.","regulator":"PMDA"},{"date":"1996-06-20","orphan":false,"company":"BAXTER HOLDING B.V.","regulator":"EMA"}],"properties":{"S":{"name":"Water solubility","units":"mg/mL","value":50},"BA":{"name":"Bioavailability","units":"%","value":5},"CL":{"name":"Clearance","units":"mL/min/kg","value":15},"Vd":{"name":"Volume of distribution","units":"L/kg","value":22},"fu":{"name":"Fraction unbound in plasma","units":"%","value":0.28},"EoM":{"name":"Fraction excreted unchanged in urine","units":"%","value":3.5},"MRTD":{"name":"Maximum Recommended Therapeutic Daily Dose","units":"µM/kg/day","value":4.470755577},"BDDCS":{"name":"Biopharmaceutical Drug Disposition Classification System","units":"","value":1},"t_half":{"name":"Half-life","units":"hours","value":32}},"drugClasses":["doxorubicin","CYP3A4 Substrates","CYP2D6 Substrates","P-glycoprotein Substrates"],"identifiers":{"NUI":"N0000147829","MMSL":"3368","NDDF":"002659","UNII":"80168379AG","VUID":"4019737","CHEBI":"CHEBI:28748","VANDF":"4018106","INN_ID":"3005","RXNORM":"142433","UMLSCUI":"C0013089","ChEMBL_ID":"CHEMBL53463","KEGG_DRUG":"D01275","DRUGBANK_ID":"DB00997","PDB_CHEM_ID":" DM2","PUBCHEM_CID":"31703","SNOMEDCT_US":"372817009","IUPHAR_LIGAND_ID":"7069","SECONDARY_CAS_RN":"25316-40-9","MESH_DESCRIPTOR_UI":"D004317","MESH_SUPPLEMENTAL_RECORD_UI":"C506643"},"indications":[{"name":"Acute lymphoid leukemia","source":"DrugCentral","umlsCui":"C0023449","snomedId":91857003},{"name":"Acute myeloid leukemia, disease","source":"DrugCentral","umlsCui":"C0023467","snomedId":91861009},{"name":"Advanced ovarian cancer","source":"DrugCentral","umlsCui":"C1140680","snomedId":363443007},{"name":"Burkitt's lymphoma","source":"DrugCentral","umlsCui":"C0006413","snomedId":118617000},{"name":"Carcinoma of breast","source":"DrugCentral","umlsCui":"C0678222","snomedId":254838004},{"name":"Carcinoma of female breast","source":"DrugCentral","umlsCui":"C3163805","snomedId":447782002},{"name":"Diffuse non-Hodgkin's lymphoma, large cell","source":"DrugCentral","umlsCui":"C0079744","snomedId":109969005},{"name":"Follicular non-Hodgkin's lymphoma","source":"DrugCentral","umlsCui":"C0024301","snomedId":308121000},{"name":"Hodgkin's disease","source":"DrugCentral","umlsCui":"C0019829","snomedId":118599009},{"name":"Invasive Bladder Malignancy","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"Kaposi's sarcoma","source":"DrugCentral","umlsCui":"C0036220","snomedId":109385007},{"name":"Kaposi's sarcoma associated with AIDS","source":"DrugCentral","umlsCui":"C0276535","snomedId":420524008},{"name":"Malignant tumor of lung","source":"DrugCentral","umlsCui":"C0242379","snomedId":363358000},{"name":"Malignant tumor of ovary","source":"DrugCentral","umlsCui":"C1140680","snomedId":363443007},{"name":"Malignant tumor of thyroid gland","source":"DrugCentral","umlsCui":"C0007115","snomedId":363478007},{"name":"Metastatic Breast Carcinoma","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"Metastatic Gastric Cancer","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"Multiple myeloma","source":"DrugCentral","umlsCui":"C0026764","snomedId":109989006},{"name":"Nephroblastoma","source":"DrugCentral","umlsCui":"C0027708","snomedId":302849000},{"name":"Neuroblastoma","source":"DrugCentral","umlsCui":"C0027819","snomedId":432328008},{"name":"Non-Hodgkin's lymphoma","source":"DrugCentral","umlsCui":"C0024305","snomedId":118601006},{"name":"Osteosarcoma of bone","source":"DrugCentral","umlsCui":"C0585442","snomedId":307576001},{"name":"Small cell carcinoma of lung","source":"DrugCentral","umlsCui":"C0149925","snomedId":254632001},{"name":"Soft or Connective Tissue Sarcoma","source":"DrugCentral","umlsCui":"","snomedId":""}],"formulations":[{"form":"INJECTABLE, LIPOSOMAL","route":"INTRAVENOUS","status":"ANDA","tradeName":"DOXORUBICIN HYDROCHLORIDE"},{"form":"INJECTABLE, LIPOSOMAL","route":"INTRAVENOUS","status":"ANDA","tradeName":"Doxorubicin Hydrochloride"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Adriamycin"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Doxorubicin Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Adriamycin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"DOXOrubicin Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Doxorubicin Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Doxorubicin hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"doxorubicin hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"NDA","tradeName":"Doxorubicin Hydrochloride"}],"offLabelUses":[{"name":"Adenocarcinoma of pancreas","source":"DrugCentral","umlsCui":"C0281361","snomedId":700423003},{"name":"Carcinoid syndrome","source":"DrugCentral","umlsCui":"C0024586","snomedId":35868009},{"name":"Chronic lymphoid leukemia, disease","source":"DrugCentral","umlsCui":"C0023434","snomedId":92814006},{"name":"Endometrial carcinoma","source":"DrugCentral","umlsCui":"C0476089","snomedId":254878006},{"name":"Ewing's sarcoma","source":"DrugCentral","umlsCui":"C0553580","snomedId":76909002},{"name":"Malignant neoplasm of liver","source":"DrugCentral","umlsCui":"C0345904","snomedId":93870000},{"name":"Malignant tumor of head and/or neck","source":"DrugCentral","umlsCui":"C0278996","snomedId":255056009},{"name":"Pancreatic Neuroendocrine Tumor","source":"DrugCentral","umlsCui":"C4305467","snomedId":717919005},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","umlsCui":"C0079773","snomedId":400122007}],"drugCentralId":960,"drugInteractions":[{"risk":"Significant","description":"DOXORUBICIN/STREPTOZOCIN [VA Drug Interaction]","interactingClass":"streptozocin"}],"contraindications":[{"name":"Anemia","source":"DrugCentral","umlsCui":"C0002871","snomedId":271737000},{"name":"Anemia due to enzyme deficiency","source":"DrugCentral","umlsCui":"C0272053","snomedId":111577008},{"name":"Asymptomatic left ventricular systolic dysfunction","source":"DrugCentral","umlsCui":"C3698411","snomedId":698592004},{"name":"Atrioventricular block","source":"DrugCentral","umlsCui":"C0004245","snomedId":233917008},{"name":"Bacterial infectious disease","source":"DrugCentral","umlsCui":"C0004623","snomedId":87628006},{"name":"Bone marrow depression","source":"DrugCentral","umlsCui":"C0151773","snomedId":307762000},{"name":"Breastfeeding (mother)","source":"DrugCentral","umlsCui":"C1623040","snomedId":413712001},{"name":"Bundle branch block","source":"DrugCentral","umlsCui":"C0006384","snomedId":6374002},{"name":"Cardiomyopathy","source":"DrugCentral","umlsCui":"C0878544","snomedId":85898001},{"name":"Conduction disorder of the heart","source":"DrugCentral","umlsCui":"C0264886","snomedId":44808001},{"name":"Deficiency of glucose-6-phosphate dehydrogenase","source":"DrugCentral","umlsCui":"C2939465","snomedId":124134002},{"name":"Disease of liver","source":"DrugCentral","umlsCui":"C0023895","snomedId":235856003},{"name":"Heart disease","source":"DrugCentral","umlsCui":"C0018799","snomedId":56265001},{"name":"Heart failure","source":"DrugCentral","umlsCui":"C0018801","snomedId":84114007},{"name":"Hepatic failure","source":"DrugCentral","umlsCui":"C0085605","snomedId":59927004},{"name":"Hyperbilirubinemia","source":"DrugCentral","umlsCui":"C0020433","snomedId":14783006},{"name":"Hyperuricemia","source":"DrugCentral","umlsCui":"C0740394","snomedId":35885006},{"name":"Leukopenia","source":"DrugCentral","umlsCui":"C0023530","snomedId":84828003},{"name":"Mycosis","source":"DrugCentral","umlsCui":"C0026946","snomedId":3218000},{"name":"Myocardial infarction in recovery phase","source":"DrugCentral","umlsCui":"C1633725","snomedId":418044006},{"name":"Myocarditis","source":"DrugCentral","umlsCui":"C0027059","snomedId":50920009},{"name":"Neutropenic disorder","source":"DrugCentral","umlsCui":"C0027947","snomedId":303011007},{"name":"Pregnancy, function","source":"DrugCentral","umlsCui":"C0032961","snomedId":289908002},{"name":"Protozoal Infection","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"Severe Cardiac Disease","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"Thrombocytopenic disorder","source":"DrugCentral","umlsCui":"C0040034","snomedId":302215000},{"name":"Viral disease","source":"DrugCentral","umlsCui":"C0042769","snomedId":34014006}]},"_fixedFields":["pubmed(2676)"],"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT07494565","phase":"PHASE2","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-05","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive","enrollment":60},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT06422806","phase":"PHASE3","title":"Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-11","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","enrollment":365},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT00066443","phase":"PHASE1, PHASE2","title":"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":93},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT00740805","phase":"PHASE1","title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-18","conditions":"Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Neoplasm","enrollment":81},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":3680},{"nctId":"NCT05210374","phase":"PHASE1","title":"Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-03-09","conditions":"Relapsed Sarcomas","enrollment":24},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT07496229","phase":"PHASE1, PHASE2","title":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","status":"NOT_YET_RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2026-03","conditions":"T-cell Lymphomas","enrollment":165},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT03937830","phase":"PHASE2","title":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-10","conditions":"Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT04008797","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-07-11","conditions":"Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular","enrollment":301},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT07486310","phase":"PHASE2","title":"Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-01","conditions":"Advanced Gastric Cancer","enrollment":30},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172},{"nctId":"NCT05610735","phase":"PHASE1, PHASE2","title":"Combination Therapy for Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Sham Sunder Kakar","startDate":"2024-09-25","conditions":"Recurrent Ovarian Cancer","enrollment":72},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT03517449","phase":"PHASE3","title":"Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-06-11","conditions":"Endometrial Neoplasms","enrollment":827},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":0},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT06047080","phase":"PHASE3","title":"An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-18","conditions":"Large B-Cell Lymphoma","enrollment":1130},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT04031677","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-01-20","conditions":"Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":250},{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT00379340","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-04-30","conditions":"Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor","enrollment":395},{"nctId":"NCT06072781","phase":"PHASE3","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2024-03-18","conditions":"Low Grade Serous Ovarian Cancer","enrollment":270},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":30},{"nctId":"NCT04729387","phase":"PHASE3","title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-22","conditions":"Ovarian Cancer","enrollment":358},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT06088290","phase":"PHASE3","title":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","status":"RECRUITING","sponsor":"PharmaMar","startDate":"2023-09-21","conditions":"Leiomyosarcoma","enrollment":450},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT07463313","phase":"PHASE2, PHASE3","title":"6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Thymoma and Thymic Carcinoma","enrollment":116},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT07286331","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-09","conditions":"Neoplasms, Endometrial","enrollment":600},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT01419561","phase":"PHASE2","title":"Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-08","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8","enrollment":140},{"nctId":"NCT07076186","phase":"PHASE2","title":"Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-02","conditions":"Uterine Leiomyosarcoma","enrollment":48},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07460986","phase":"PHASE1, PHASE2","title":"A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07","conditions":"Sarcoma of Soft Tissue","enrollment":278},{"nctId":"NCT05959889","phase":"NA","title":"Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-03-01","conditions":"Breast Cancer, Doxorubicin Induced Cardiotoxicity","enrollment":50},{"nctId":"NCT05661201","phase":"PHASE1","title":"NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-04-12","conditions":"Solid Tumor, KRAS Mutation-Related Tumors","enrollment":24},{"nctId":"NCT05581030","phase":"PHASE1","title":"CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT07254091","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2026-01-30","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT06745076","phase":"PHASE2","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-03-06","conditions":"Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","enrollment":125},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT07044336","phase":"PHASE3","title":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-01","conditions":"Endometrial Cancer, Malignant Solid Tumour","enrollment":700},{"nctId":"NCT06401330","phase":"PHASE3","title":"A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-04-15","conditions":"Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor","enrollment":1656}],"_emaApprovals":[{"date":"","name":"Liposomal Doxorubicin","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL359744","moleculeType":"Small molecule","molecularWeight":"579.99"},"administration":{"formulations":[{"form":"INJECTABLE, LIPOSOMAL","route":"INTRAVENOUS","tradeName":"DOXORUBICIN HYDROCHLORIDE"},{"form":"INJECTABLE, LIPOSOMAL","route":"INTRAVENOUS","tradeName":"Doxorubicin Hydrochloride"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","tradeName":"Adriamycin"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","tradeName":"Doxorubicin Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"Adriamycin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"DOXOrubicin Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"Doxorubicin Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"Doxorubicin hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"doxorubicin hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"Doxorubicin Hydrochloride"}]},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"NUI":"N0000147829","MMSL":"3368","NDDF":"002659","UNII":"80168379AG","VUID":"4019737","CHEBI":"CHEBI:28748","VANDF":"4018106","INN_ID":"3005","RXNORM":"142433","UMLSCUI":"C0013089","chemblId":"CHEMBL359744","ChEMBL_ID":"CHEMBL53463","KEGG_DRUG":"D01275","DRUGBANK_ID":"DB00997","PDB_CHEM_ID":" DM2","PUBCHEM_CID":"31703","SNOMEDCT_US":"372817009","IUPHAR_LIGAND_ID":"7069","SECONDARY_CAS_RN":"25316-40-9","MESH_DESCRIPTOR_UI":"D004317","MESH_SUPPLEMENTAL_RECORD_UI":"C506643"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"1995-present","companyName":"Pfizer","relationship":"Originator"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"32.0 hours","clearance":"15.0 mL/min/kg","bioavailability":"5.0%","fractionUnbound":"0.28%","volumeOfDistribution":"22.0 L/kg"},"publicationCount":2687,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01DB01","allCodes":["L01DB01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 29","pmid":"41905747","title":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","journal":"British journal of haematology"},{"date":"2026 Mar 27","pmid":"41894179","title":"Old drug, new data: Broadening the therapeutic armamentarium for desmoid tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2026 Mar 19","pmid":"41855500","title":"Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.","journal":"Blood advances"},{"date":"2026 Apr","pmid":"41852878","title":"Self-navigated NIR-II thermophoretic liposome nanomotors for directed tumor delivery and enhanced chemotherapy.","journal":"Materials today. Bio"},{"date":"2026","pmid":"41815546","title":"Case Report: A successfully managed case of SMARCA4-deficient undifferentiated gastric carcinoma.","journal":"Frontiers in oncology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1974","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":9,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:53.192817+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}